MNG436
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.464
- KRAS_SIGNALING_DN+0.424
- SPERMATOGENESIS+0.209
- COAGULATION+0.201
- MYOGENESIS+0.172
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.122
- KRAS_SIGNALING_UP+0.071
- APICAL_SURFACE+0.065
- INFLAMMATORY_RESPONSE+0.054
- ANGIOGENESIS+0.028
Top 10 suppressed
- MYC_TARGETS_V2-0.624
- OXIDATIVE_PHOSPHORYLATION-0.598
- MYC_TARGETS_V1-0.591
- PROTEIN_SECRETION-0.570
- UNFOLDED_PROTEIN_RESPONSE-0.559
- MTORC1_SIGNALING-0.554
- DNA_REPAIR-0.523
- E2F_TARGETS-0.520
- MITOTIC_SPINDLE-0.520
- G2M_CHECKPOINT-0.496
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG923 | — | — | 0.975 |
| 2 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.971 |
| 3 | MDT-AP-1143 | Med | Medulloblastoma | 0.964 |
| 4 | SJEPD001523_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.962 |
| 5 | MNG1118 | — | — | 0.961 |
| 6 | SRR1340301 | GTEX | — | 0.961 |
| 7 | SRR1468974 | GTEX | — | 0.958 |
| 8 | MNG597 | — | — | 0.958 |
| 9 | SRR1474886 | GTEX | — | 0.958 |
| 10 | SRR1348861 | GTEX | — | 0.957 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.464 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.424 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.209 | Inavolisib | — uncovered |
| COAGULATION | 0.201 | Binimetinib | — uncovered |
| MYOGENESIS | 0.172 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.122 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.071 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.065 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.054 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.028 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.004 | Idelalisib | — uncovered |